You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
PostScript
Testing for JAK2V617F mutation across specimen types yields concordant results
  1. I Mirza,
  2. D Sekora,
  3. C Frantz
  1. Division of Molecular Pathology, Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Canada
  1. Dr I Mirza, Department of Laboratory Medicine & Pathology, University of Alberta, 4B4.31 WMC, 8440-112 Street, Edmonton, AB T6M 2E7, Canada; imirza{at}cha.ab.ca

https://doi.org/10.1136/jcp.2007.054379

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Chronic myeloproliferative neoplasms (CMPN) are a group of hematopoietic stem cell disorders associated with abnormal blood cell production and bone marrow (BM) morphology. Myeloid cells from the majority of patients with polycythaemia vera (PV) and approximately half of those with essential thrombocythaemia (ET) and primary myelofibrosis (PMF) carry the JAK2V617F mutation.1–3 Recent proposed revisions to the World Health Organization (WHO) diagnostic criteria for these disorders include the presence of JAK2V617F mutation as a major criterion for diagnosis.4 Although various studies have shown that JAK2 mutation testing can be successfully performed on peripheral blood (PB),1–3 bone marrow aspirate (BMA),5 or BM biopsy,6 7 comparison …

    View Full Text